On 8 MAY Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) reported ($0.25) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.25), during the same quarter last year, the company posted ($0.29) earnings per share. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) weekly performance is 11.69%. On last trading day company shares ended up $3.63. Analysts mean target price for the company is $6.00. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) distance from 50-day simple moving average (SMA50) is 10.54%.
On 28 MAY Fibrocell Science Inc (NYSEMKT: FCSC) announced that Progenitor Cell Therapy (PCT), a subsidiary of NeoStem, Inc. (NASDAQ:NBS), has been engaged by Fibrocell’s collaborator, Intrexon Corporation (NYSE:XON), to provide production capabilities in the generation of cell therapies for the rare disease Recessive Dystrophic Epidermolysis Bullosa (RDEB). Fibrocell Science Inc (NYSEMKT: FCSC) shares fell -2.99% in last trading session and ended the day on $2.92. FCSC return on assets is -83.00%. Fibrocell Science Inc (NYSEMKT: FCSC) quarterly performance is -48.04%.
On 22 MAY Agile Therapeutics Inc (NASDAQ:AGRX) announced the pricing of its initial public offering of 9,166,667 shares of its common stock at a public offering price of $6.00 per share. Agile Therapeutics has granted the underwriters a 30-day option to purchase up to an aggregate of 1,375,000 additional shares of common stock at the initial public offering price to cover any over-allotments. Agile Therapeutics Inc (NASDAQ:AGRX) shares moved down -7.04% in last trading session and was closed at $5.81, while trading in range of $5.70 – $6.30. Agile Therapeutics Inc (NASDAQ:AGRX) year to date (YTD) performance is 4.87%.
On 19 MAY Sophiris Bio Inc (NASDAQ:SPHS) announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”). The Company intends to use the initial proceeds to support a proof of concept study of PRX302 as a treatment for localized prostate cancer. Sophiris Bio Inc (NASDAQ:SPHS) ended the last trading day at $2.58. Company weekly volatility is calculated as 5.96% and price to cash ratio as 0.76. Sophiris Bio Inc (NASDAQ:SPHS) showed a negative weekly performance of -12.84%.
On 30 MAY Hospira, Inc. (NYSE:HSP) reported $0.60 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.49 by $0.11. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the prior year, the company posted $0.52 earnings per share. The company’s quarterly revenue was up 6.3% on a year-over-year basis. On average, analysts predict that Hospira will post $2.19 earnings per share for the current fiscal year. Hospira, Inc. (NYSE:HSP) net profit margin is 1.40% and weekly performance is 2.92%. On last trading day company shares ended up $50.03. Analysts mean target price for the company is $43.64. Hospira, Inc. (NYSE:HSP) distance from 50-day simple moving average (SMA50) is 9.95%.